Jury Favors AbbVie in the Fifth TRT Bellwether Trial
Jury Favors AbbVie in the Fifth TRT Bellwether Trial
Introduction
AbbVie Inc. won yet another lawsuit on June 14 over claims that its AndroGel caused a man's deep vein thrombosis (DVT). This is the fifth testosterone replacement therapy bellwether trial, which began on June 5, in the Illinois State Court for a plaintiff.
The plaintiff filed a lawsuit in 2014 after suffering from DVT in April 2013 and in late 2015. He blamed Androgel use for both incidents. The federal jury dismissed the plaintiff's allegation that AndroGel's use led to his blood clot. Last month, a plaintiff and his wife lost to AbbVie, as the jury stated that the drug was not responsible for his bilateral pulmonary embolism that occurred in February 2008.
Testosterone Replacement Therapy lawsuits are centralized before U.S. District Judge Matthew Kennelly in the Northern District of Illinois as a part of federal multidistrict litigation (MDL No. 2545; In Re: Testosterone Replacement Therapy Products Liability Litigation).
Comments
Latest News
Cencora Directors Settle Opioid Oversight Case for $111M
Categories: Opioids
Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids…
Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…
FDA Adds New Warnings on Long-Term Opioid Risks
Categories: Opioids
Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.
…